---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-328100"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:26:05.278901+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B

## Summary
- Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.
- Long-term capital of $225M fully drawn; launch capital of $225M with $50M drawn to date.
- Royalty Pharma to receive $523M in quarterly repayments over 10 years (1.9x); $20M repaid through Sep 2025.
- Following approval, Cytokinetics can draw additional $175M within 12 months, repayable at 1.9x over 10 years.
- MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

## SEC filing metadata
- accession: 0001193125-25-328100
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/0001193125-25-328100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/d35067d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-328100
- JSON: https://secwatch.observer/filing/0001193125-25-328100.json
- Plain text: https://secwatch.observer/filing/0001193125-25-328100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.